-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 27, 2021, the FDA approved Bristol-Myers-Squibb's multiple sclerosis drug Zeposia for the treatment of moderate to severe active ulcerative colitis (UC).
Achieving this transition requires some commercial operations, and there is a general price gap between MS and UC drugs.
At present, various types of bioinjectable preparations are in a leading position in the UC market, including tumor necrosis factor inhibitors, such as AbbVie's Humira; Takeda's Entyvio; Johnson & Johnson's IL-12/23 antibody.
Zeposia proved its value in UC in the Phase 3 True North study.
Zeposia will also compete with Pfizer Pfizer's oral JAK inhibitor Xeljanz.
Although Zeposia is now the first S1P drug to enter UC, competition is brewing.